Home > Full Text Reviews > Drug Class Review: Quick-relief...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cover of Drug Class Review: Quick-relief Medications for Asthma

Drug Class Review: Quick-relief Medications for Asthma

Final Report Update 1

Drug Class Reviews

Susan L Norris, MD, MPH, Tarra K McNally, MPH, MA, and Sujata Thakurta, MPAHA.

Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright and Permissions

Asthma is a chronic inflammatory disorder of the airways. In susceptible individuals this inflammation causes recurrent episodes of wheezing, breathlessness, cough, and other symptoms. Asthma medications fall into 2 general classes: medications for long-term control and medications for quick relief of airflow obstruction and symptoms. Medications for quick relief of bronchoconstriction and acute symptoms include short-acting beta2-agonists and anticholinergics. The purpose of this review is to compare the benefits and harms of short-acting beta2-agonists and ipratropium bromide used for quick relief of asthma symptoms.

Original report:
Susan L. Norris, MD, MPH
Po-Yin Yen, MS
Tracy L. Dana, MLS
Byron R. Care, MA
Brittany U. Burda

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Suggested citation:

Norris S, McNally T, Thakurta S. Drug class review: Quick-relief medications for asthma. 2008. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

PMID: 21089252

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...